Allogeneic Anti-CD19 CAR-T for Refractory Graves' Disease

EARLY_PHASE1RecruitingINTERVENTIONAL

Enrollment

Participants

Timeline

Start Date

August 10, 2025

Primary Completion Date

December 31, 2026

Study Completion Date

March 31, 2027

Conditions

Graves Disease

Interventions

BIOLOGICAL

Allogeneic CAR-T

The participants will receive one dose of allogeneic CAR-T

Trial Locations (1)

RECRUITING

Zhongshan Hospital Fudan University, Shanghai

All Listed Sponsors

lead

Shanghai Zhongshan Hospital

OTHER